<DOC>
	<DOCNO>NCT00725855</DOCNO>
	<brief_summary>The purpose study evaluate effect nicotinic alpha-7 MEM 3454 P50 sensory gating patient Schizophrenia . The hypothesis MEM 3454 normalize P50 ratio . Data produce study provide useful information regard value P50 efficacy biomarker , provide evidence optimal dose MEM 3454 additional P50 study .</brief_summary>
	<brief_title>A Single-Center , Double-Blind ( DB ) Study MEM 3454 P50 Sensory Gating Mismatch Negativity Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Male female subject 18and 55 year age . 2 . Fluent English , even English primary language . 3 . Able provide inform consent . 4 . DSM IVR primary diagnosis schizophrenia ( subtype ) , assess use structure diagnostic interview ( SCID CT ) . 5 . Few extrapyramidal symptom ( EPS ) screening , define SAS &lt; 6 . 6 . Negative urine drug screen ( UDS ) . 7 . Negative cotinine test . 8 . Clinically stable , judged investigator , nonacute phase least 12 week . At least one month dose antipsychotic medication . Current risk suicide , history suicidal behavior within last 6 month . Hospitalized psychiatric symptom past 3 month . Other psychiatric diagnosis . Substance abuse/dependence ( nicotine caffeine ) within last 6 month accord SCIDCT . Currently smoke , nicotine replacement therapy , smoke cessation medication remedy , include Varenicline ( Chantix ) . Any medical condition , judge Investigator , may interfere subject ' participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>P50 Sensory Gating</keyword>
	<keyword>Mismatched Negativity</keyword>
</DOC>